NewsBenzingaBioMarin Pharmaceutical Expects Q3 Pre-Tax Charges Of $283M For Bought IPR&d Expense; Expects $1.5 Unfavorable Impact To GAAP And Non-gaap Diluted EPS For Q3; Expects Total Pre-Tax Charges Of $320M For FY26 From Alesta Acquisition; Expects $1.55... BioMarin Pharmaceutical Expects Q3 Pre-Tax Charges Of $283M For Bought IPR&d Expense; Expects $1.5 Unfavorable Impact To GAAP And Non-gaap Diluted EPS For Q3; Expects Total Pre-Tax Charges Of $320M For FY26 From Alesta Acquisition; Expects $1.55... Benzinga 2026.10.06 20:31 (GMT+0) Open on Benzinga Other news Solana ETFs End a 14-Week Buying Streak With Their Largest Weekly Exit Amazon Eyes $7B AI Startup Deal as It Pushes Into AI Chips - TipRanks.com SOL spot ETFs saw net outflows of $24.8109 million last week Ethereum spot ETFs saw $542 million in net outflows last week, with BlackRock's ETHA leading at $477 million Elon Musk Takes Swipe at Billionaire Mukesh Ambani's 'De Facto' Monopoly in India: 'Absurd Hypocrisy and Hyperbole' on Starlink Competition DATA Network joins Sui and Walrus to scale the supply chain for AI training data
Ethereum spot ETFs saw $542 million in net outflows last week, with BlackRock's ETHA leading at $477 million
Elon Musk Takes Swipe at Billionaire Mukesh Ambani's 'De Facto' Monopoly in India: 'Absurd Hypocrisy and Hyperbole' on Starlink Competition
